Similar Articles |
|
Chemistry World May 23, 2012 Andy Extance |
Drug watchdogs mark out global territory The US Food and Drug Administration has published plans to ensure that American citizens continue to enjoy access to safe drugs, even as the regulatory pressures of globalization grow. |
Pharmaceutical Executive May 1, 2005 Sarah Houlton |
Global Report: Iron Fist The United Kingdom is hardening its stance on pharma industry issues. |
Pharmaceutical Executive August 1, 2008 Sarah Houlton |
Jumping the Gun The Association of the British Pharmaceutical Industry and the British government have come up with a solution for price regulation that isn't as bad as the industry had feared. |
Chemistry World October 23, 2013 Sarah Houlton |
Pharma manufacturing woes dog industry Many problems arise from quality control failures, according to Nicholson Price from Harvard Law School's Petrie-Flom center for health law policy, biotechnology and bioethics, this is not the only problem -- regulatory constraints can prevent process improvements being made. |
Chemistry World June 21, 2010 Sarah Houlton |
Recalling pharma Recent drug withdrawals and manufacturing failures have highlighted the importance of ensuring that the medicines patients take contain what it says on the label. |
Chemistry World June 26, 2012 Sarah Houlton |
Roche rapped for side-effect reporting failure Roche has been rapped by the European Medicines Agency for failing to report a large number of potential drug side-effects. The UK's Medicines and Healthcare products Regulatory Agency identified deficiencies in the company's medicine safety reporting system. |
Pharmaceutical Executive August 1, 2006 Patrick Clinton |
From the Editor: Take Your Seat There's a lot to accomplish in the pharmaceutical industry. But considering what the industry has done in 25 years, it's not impossible. |
Chemistry World March 17, 2014 Phillip Broadwith |
UK to fast-track access to critical medicines Critically ill patients in the UK could receive new medicines before they are formally approved under a new scheme beginning in April. |
Pharmaceutical Executive May 1, 2014 Hansen & Melick |
Does Your Rigor Match Your Risk? Digital technology has changed the risk relationship between brands, HCPs, and patients; it's vital to get that technology working right the first time. |
Chemistry World October 10, 2012 Maria Burke |
Illegal medicines seized in worldwide operation During the nine-day operation, coordinated by INTERPOL and involving 100 countries, around 18,000 illegal online pharmacy websites were shut down and 79 people were arrested. |
Pharmaceutical Executive January 1, 2006 Sarah Houlton |
Global Report: The UK's New Code of Conduct Pharma companies' relationships with doctors are being tightened in the United Kingdom, after a major overhaul of the Association of the British Pharmaceutical Industry's Code of Practice. |
Chemistry World December 22, 2011 Sarah Houlton |
Pharma braces for patent cliff impact It remains to be seen quite how far Lipitor sales will fall. Ranbaxy has six months of exclusivity for generic competition. |
Pharmaceutical Executive December 1, 2011 |
UK Report: Keep Calm and Carry On ... Differently Even as the global economic roller coaster affects one of the country's dearest public institutions, the National Health Service, there is still reason for optimism in these times of austerity. |
Pharmaceutical Executive December 1, 2006 Sarah Houlton |
Global Report: Not So NICE A new manifesto by the Association of the British Pharmaceutical Industry is designed to improve drug access in the UK, where industry has worried for years about poor uptake of new medicines. |
Pharmaceutical Executive April 1, 2012 Feam & Lagus |
Providing Access Now While regulatory frameworks and medical practices differ between countries, many patients still need early access to new drugs. Industry can help. |
Pharmaceutical Executive October 1, 2005 Philip A. George |
Backpage: Under Surveillance Doctors and consumers don't doubt that pharma benefits society. But in the eyes of the public, industry efforts to monitor postmarket safety come up short. |
Pharmaceutical Executive December 1, 2005 Patrick Clinton |
PharmExec's 2006 Forecast The 2006 pharmaceutical industry is under assault from Congress, the press and the public, add a complex government program that will unimaginably change industry economics, and subtract revenues from off-patent products. |
Pharmaceutical Executive January 1, 2012 Jill Wechsler |
New Year, New Issues Look for action in 2012 on drug access, shortages, innovation, and transparency. The 800-pound gorilla in the room is the looming Supreme Court decision on the constitutionality of the Obama health reform legislation. |
Pharmaceutical Executive October 1, 2011 |
Regulation and Reputation: Still Two Solitudes The pharmaceutical and biopharmaceutical industries will only be able to continue providing patients with safe and effective medicines if the price is affordable. This will involve changes in attitudes by the industry, regulators, politicians, and the public. |
Pharmaceutical Executive July 1, 2009 Patrick Clinton |
What to Buy In the long run, pharma wants to sell health, not just drugs. |
Pharmaceutical Executive February 1, 2012 Sarah Krug |
Introducing the 'Chief Patient Officer' Now is the time for pharma companies to appoint a Chief Patient Officer, a new position designed to build an accord around patient trust. |
CRM February 2, 2003 David Myron |
Vertical Focus: Pharmaceuticals Pharmaceutical companies are prolonging the good health of their customers -- and the CRM industry. Largely influenced by retiring Baby Boomers, lack of FDA-approved drugs in the pipeline, and direct selling campaigns, the industry is becoming more customer-focused. |
Chemistry World January 30, 2007 Bea Perks |
BBC and GSK Battle Over Seroxat The UK pharmaceutical giant, which has spent the past few years fighting off accusations of risks associated with its market-leading anti-depressant, has rejected fresh claims that it improperly withheld medical trial information in the 1990s. |
Pharmaceutical Executive September 1, 2012 Stan Bernard |
The Payer C Change: From Customers to Competitors "Payers have evolved to become powerful global contenders with pharma for increasingly limited funding of drug budgets." Understanding why and how this payer shift to dominance occurred is critical for pharmaceutical professionals in adjusting their business model. |
Pharmaceutical Executive May 1, 2011 Julian Upton |
UK Stakeholders Have Their Say on Value-Based Pricing The UK coalition government's consultation on the intro of value-based pricing has invited caution and resistance. |
Chemistry World May 2006 Bea Perks |
Editorial: Generics in the Dock The manufacturers of generic medicines in the U.K. must work harder to guard their good reputation. Or perhaps, manufacturers of generic medicines must work harder to counter their bad reputation. |
Chemistry World July 25, 2006 Bea Perks |
Clinical Chaos Under Scrutiny Clinical trials of new drugs need to be tightened up, according to an expert group convened in the aftermath of UK trials that left six people fighting for their lives. |
Chemistry World January 29, 2008 Richard Van Noorden |
Tiny Magnets to Repel Drug Counterfeiters A large pharmaceutical packaging company is hoping that nanotech security tags devised by a small Singaporean firm will help it combat counterfeit drugs. |
Chemistry World June 18, 2008 Ananyo Bhattacharya |
Deal on NHS drugs set to trim pharma profits An agreement between the UK government and the pharmaceutical industry will cut around five per cent off the cost of medicines sold to the National Health Service |
Chemistry World October 1, 2012 Andrew Turley |
Pharma should 'double output by 2022' The President's Council of Advisors on Science and Technology advises that pharmaceutical companies should set a goal of doubling output of 'innovative new medicines that meet critical public health needs' over the next 10 -- 15 years. |
Pharmaceutical Executive December 1, 2008 Patrick Clinton |
Reason to Believe Here are a few things to be optimistic about in the pharmaceutical industry. |
Chemistry World January 3, 2013 Sarah Houlton |
2012 pharma industry roundup It may have been a relatively quiet year in terms of mergers and acquisitions, but the pharma industry nonetheless made plenty of headlines in 2012. |
Chemistry World March 20, 2008 Richard Van Noorden |
UK Drug Firms to Slash Research and Jobs The UK pharmaceutical industry is expecting to cut jobs and investment in R&D following an alarming slump in confidence in the UK market. |
Pharmaceutical Executive April 1, 2009 Patrick Clinton |
Dear Commissioner... Unsolicited advice for FDA's next leader: Keep it real, fight popular delusions, and somehow, please, defend the agency. |
Pharmaceutical Executive June 1, 2014 dos Santos & Leskin |
Social Media and the In-House Counsel Social media poses a regulatory and litigation maze that must be carefully navigated by pharmaceutical companies. |
BusinessWeek November 19, 2009 Catherine Arnst |
Why Drugmakers Don't Twitter The FDA has so far failed to craft rules clarifying how pharmaceutical companies can participate in online discussions. |
Chemistry World May 7, 2014 Phillip Broadwith |
UK regulator warning over online herbal remedies The UK's Medicines and Healthcare products Regulatory Agency has found that several herbal medicines available over the internet are contaminated with prescription-only drugs or toxic heavy metals. |
Pharmaceutical Executive October 1, 2011 Daniel Vasella |
Heart of Success: Patient-Centric R&D Drug discovery must remain a core competency of industry. The future success of individual companies will be tightly linked to success in R&D. |
Chemistry World March 25, 2010 Rebecca Trager |
Big pharma scores in US healthcare reform President Obama has signed the biggest US healthcare reform since the 1960s, and although it is largely seen as a victory for the pharmaceutical industry, some analysts are characterising it as a 'double-edged sword'. |
Pharmaceutical Executive September 1, 2005 Wolfgang Klietmann |
Thought Leader: (Eco)systemic Change The author discusses how various players within the healthcare system interact. |
Pharmaceutical Executive March 1, 2012 B. Brett Heavner |
Judging a Pill by its Cover Pharmaceutical trade dress is an effective marketing tool that helps boost product recognition for consumers. It's worth protecting. |
Chemistry World April 2007 Richard Barker |
Comment: Pricing Pills An Office of Fair Trading report claims The UK's National Health Service is paying over the odds for its drugs, but this is not so. Medicine prices are 21% lower in real terms than ten years ago. |
Pharmaceutical Executive October 1, 2005 |
Public Relations: Communications Delivery Chain An interview with Nanccy Turett, president of Edelman Health on how, to regain consumers' trust, pharma must better communicate its mission, goals, and policies. |
Pharmaceutical Executive October 1, 2011 |
The Legacy of High Expectations Andrew Witty, Chairman & CEO, GlaxoSmithKline, believes the pharmaceutical industry will continue to make a significant contribution to society if it continues to improve the way it goes about its work. |
Pharmaceutical Executive January 1, 2009 Stan Bernard |
Pharma vs. Pharma The most successful pharmaceutical companies will be those that can transform as the industry itself transforms. |
Pharmaceutical Executive June 1, 2013 Tom Reynolds |
Finding Strategic Levers in the Supply Chain Customer-focused supply-chain capabilities are becoming a more important part of a company's competitive advantage. |
The Motley Fool January 31, 2007 Brian Lawler |
FDA Says Hurray for More Drug Safety The FDA outlines its proposal to increase drug safety. Whatever the FDA does, pharmaceutical investors should hope that its renewed interest in drug safety doesn't make the already lengthy process of bringing drugs to market any longer. |
InternetNews July 27, 2010 |
Oracle Debuts Drug-Tracking App for Big Pharma With its new Pedigree and Serialization Manager, Oracle is pitching an application to pharmaceutical companies that will enable them to track the movement of drugs across the supply chain. |
Pharmaceutical Executive February 1, 2011 Jon Zifferblat |
China: Business as UNusual If there is one market that requires a click on the 'refresh' button, it's China. General Biologic provides a snapshot of what's ahead for Big Pharma in the country |
Chemistry World March 21, 2013 Andy Extance |
Court convicts ex-Aptuit researcher over drug data Steven Eaton, a former employee at drug discovery and development firm Aptuit's Riccarton site in Scotland, produced flawed data over six years. |